Axial spondyloarthritis | All | CZP low (< 20 mg/L) | CZP high (≥ 20 mg/L) | P value |
(n = 116) | (n = 26) | (n = 90) | ||
Age, years, mean (SD) | 42 (12) | 43 (11) | 41 (12) | 0.61 |
Female, n (%) | 54 (47) | 14 (54) | 40 (44) | 0.40 |
Disease duration, years, median (IQR)* | 2.6 (0.6–14.1) | 3.6 (1.7–11.7) | 2.3 (0.3–14.8) | 0.39 |
ASDAS-CRP, mean (SD) | 2.6 (1.0) | 2.4 (0.9) | 2.7 (1.0) | 0.28 |
HLA-B27 positive, n (%) | 87 (75) | 17 (65) | 70 (81) | 0.09 |
Prior use of biologic DMARD, n (%) | 39 (34) | 10 (40) | 29 (33) | 0.54 |
Concomitant conventional synthetic DMARD, n (%) | 22 (19) | 2 (8) | 20 (22) | 0.10 |
Rheumatoid arthritis | All | CZP low (< 20 mg/L) | CZP high (≥ 20 mg/L) | P value |
(n = 91) | (n = 23) | (n = 68) | ||
Age, years, mean (SD) | 54 (14) | 54 (16) | 54 (14) | 0.90 |
Female, n (%) | 72 (79) | 13 (57) | 59 (87) | < 0.05 |
Disease duration, years, median (IQR)** | 10.1 (2.1–18.9) | 17.4 (6.8–23.5) | 7.4 (2.0–14.9) | 0.10 |
DAS28, mean (SD) | 4.0 (1.4) | 3.5 (1.1) | 4.2 (1.5) | 0.08 |
RF-positive, n (%) | 55 (61) | 12 (52) | 43 (66) | 0.23 |
Anti-CCP positive, n (%) | 59 (66) | 13 (57) | 46 (71) | 0.21 |
Prior use of biologic DMARD, n (%) | 44 (48) | 14 (64) | 30 (45) | 0.13 |
Concomitant conventional synthetic DMARD, n (%) | 67 (74) | 16 (70) | 51 (75) | 0.53 |
Psoriatic arthritis | All | CZP low (< 20 mg/L) | CZP high (≥ 20 mg/L) | P value |
(n = 61) | (n = 17) | (n = 44) | ||
Age, years, mean (SD) | 50 (11) | 48 (12) | 51 (11) | 0.45 |
Female, n (%) | 40 (66) | 12 (71) | 28 (64) | 0.61 |
Disease duration, years, median (IQR)*** | 6.6 (1.5–13.2) | 5.4 (1.3–13.5) | 6.9 (1.6–13.2) | 0.76 |
DAS28, mean (SD) | 3.9 (1.3) | 3.9 (1.8) | 3.9 (1.2) | 0.99 |
Prior use of biologic DMARD, n (%) | 30 (49) | 10 (59) | 20 (47) | 0.39 |
Concomitant conventional synthetic DMARD, n (%) | 38 (67) | 8 (53) | 30 (71) | 0.20 |